Aldeyra Therapeutics, Inc. (ALDX)
Chart Events
Performance Outlook
| Previous Close | 7.27 |
| Open | 7.28 |
| Bid | 7.61 x 800 |
| Ask | 7.63 x 800 |
| Day's Range | 6.96 - 7.65 |
| 52 Week Range | 2.36 - 9.81 |
| Volume | |
| Avg. Volume | 1,092,780 |
| Market Cap | 442.633M |
| Beta (5Y Monthly) | 1.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.08 |
| Earnings Date | Mar 09, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.13 |
- Zacks
Aldeyra Therapeutics, Inc. (ALDX) Now Trades Above Golden Cross: Time to Buy?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
- Motley Fool
Aldeyra Therapeutics (ALDX) Q2 2022 Earnings Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Aldeyra Therapeutics second quarter 2022 financial results conference call. With me today is Dr. Todd Brady, our president and chief executive officer. Please note that this morning's conference call contains forward-looking statements regarding future events and the future performance of Aldeyra.
- Business Wire
Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights
LEXINGTON, Mass., August 05, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the quarter ended June 30, 2022.
